News

A neurologist and movement disorders specialist at the University of California, Los Angeles (UCLA), is working to develop a way to help Parkinson’s disease researchers better assess and recruit Black patients into clinical studies. If successful, the tool planned by Jennifer Adrissi could be adapted for use…

Members of the Support Group for Black Patients with Parkinson’s Disease took part in the Parkinson Council’s Walk to Stamp Out Parkinson’s event in November and raised more than $3,400, helping the Council to come within 70% of its $400,000 fundraising goal. The support group, which was launched in…

Alterity Therapeutics‘ ATH434 improved motor performance and overall function in non-human primates with induced Parkinson’s disease, according to data presented at the recent Future of Parkinson’s Disease Conference 2023. The investigational therapy is currently undergoing evaluation in an open-label biomarker study called ATH434-202 (NCT05864365), which has…

Phasing out fossil fuels could save an estimated 5.1 million lives each year worldwide by preventing deaths attributed to ambient air pollution, including those likely due to neurodegenerative diseases such as Parkinson’s, a study has found. Transitioning to clean, renewable energy sources is not only an effective intervention to…

The University of Buffalo (UB) now has a Parkinson Voice Project (PVP) SPEAK OUT! center, featuring its signature speech therapy program, which aims to help people with Parkinson’s disease — at no cost to them — maintain their voices, minimize any swallowing problems, and better communicate with,…

Annovis Bio has announced the last patient completed the final visit in its Phase 3 clinical trial testing buntanetap for people with early-stage Parkinson’s disease. Since the study was initiated in August 2022, more than 616 patients were screened, 523 enrolled, and 471 completed the study across…

The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has given Mission Therapeutics clearance to launch a Phase 1 clinical trial testing MTX325, its experimental oral therapy for Parkinson’s disease. “The MHRA’s authorisation marks a major step forward in our mission to develop MTX325 as a disease-modifying therapy for…

Nanoplastics — very tiny particles found in the environment when plastic breaks down — that reach a person’s brain can increase the risk of Parkinson’s disease or its progression by prompting the protein alpha-synuclein to clump and turn toxic. “A recent study found that polystyrene plastic pollution, among a…

Two leading nonprofit institutes have launched the GA4GH & INCF Neuroscience Community to better connect researchers around the world studying Parkinson’s disease and other brain disorders, and to improve data sharing globally. The goal of this new network, its creators say, is to tackle the complexity underlying disorders like…

The Parkinson’s Foundation presented the Movement Disorders Clinic at the University of Arkansas for Medical Sciences (UAMS) with a plaque last month that marks its recent designation as a Comprehensive Care Center. The university was one of six centers named in June 2022 as part of the Foundation’s…